CLINICAL-PSYCHOLOGICAL CHARACTERISTICS IN PATIENTS WITH A PERMANENT FROM OF ATRIAL FIBRILLATION

Atrial fibrillation (AF) is the most common chronic heart rhythm disorder that occurs in 1-2% of people in the general population. It is estimated that 2.2 million Americans and 6 million Europeans suffer from paroxysmal and persistent AF. AF has been shown to be associated with an increased risk of stroke, heart failure and death. However, significant importance in the occurrence and progression of AF is given to extracardiac factors, such as the emotional state of the patient, the presence of traumatic situations. Therefore, the as-sessment of psycho-emotional status in patients with AF, especially the presence of anxiety and depression, which according to the literature contribute to the development of arrhythmias, is a very important task. Studies focusing on the role of depression and anxiety in AF patients have shown that 23,3% of patients with paroxysmal and 28,4% of patients with persistent AF have increased levels of clinical anxiety and depression. Therefore, further research is needed to clarify the clinical significance, diagnostic efficacy of new treatments and screening for atrial fibrillation to reduce the risk of its complications. The aim of the study was to compare the effec-tiveness of treatment of persistent atrial fibrillation by analyzing psychometric scales. Materials and methods. We examined 62 pa-tients with a permanent form of atrial fibrillation on the background of psycho-emotional disorders and without them. In order to compare the effectiveness of treatment, patients were divided into 4 groups: 1 group (n=16) con-sisted of patients who received standard treatment, group 2 (n=15) - standard treatment + mebicar. The third group (n=15) included patients receiving carvedilol. The fourth group (n=16) consisted of patients to whom carvedilol and mebicar were added to standard treatment. Assess-ment of mental status was determined by the self-assessment of psychosocial stress L. Reeder, the scale of perceived stress-10 (stress level) and the HADS scale (assessment of anxiety and depression), PHQ-9. We used the PHQ-15 health questionnaire, questionnaire to identi-fy social factors that may affect health, the quality of life scale. The results of the study show that the addition of mebicar to the standard of treatment helped to reduce clinical and psychopathocharacterological signs of atrial fibrillation and anxiety and depressive disorders, with a significant difference in the study groups. At the same time, patients in the standard treatment and standard treatment + carvedilol groups had an increase in blood pressure, heart rate, while the addition to standard treat-ment + carvedilol, mebicar, on the contrary, helped to reduce blood pressure, heart rate, heart rate and mean blood pressure (p2<0.01) Conclusions. The use of mebicar in the complex therapy of patients with permanent atrial fibrillation leads to a decrease in anxiety, increased tolerance of psycho-emotional load, a significant reduction in autonomic imbalance, and potentiates the manifestations of depressive mood, improves the quality of life of patients. Whereas, the use of carvedilol and mebicar on the background of basic therapy increases exercise tolerance, has a positive effect on changes in blood pressure due to blockade of α, β1-adrenoceptors.